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Review of karyotypic data from low grade glial brain tumors, specifically pilocytic
astrocytomas, and correlation of genetic aberrations with tumor recurrence.
Linda D Cooley, Scott C Smith, Lisa Warren, Melissa Gener, Kevin Ginn, John Herriges
Children’s Mercy Hospitals and Clinics, Kansas City, Missouri, USA
Abstract: Brain tumors are the most common solid tumor of childhood.
Approximately 50% of pediatric CNS tumors are low grade gliomas (WHO grade
I or II) and Pilocytic astrocytoma (PA) is the most common accounting for 33% of
all gliomas in children 0-14 years and ~18% of all childhood brain tumors.
Prognosis with this slow-growing tumor is excellent; 10 year overall survival of
~95%. However, event free survival averages ~50%. Patient age and extent of
tumor resection are key prognostic factors; tumor location and size impact
resection and outcome. Histopathological features indicate PA is a benign tumor
and rarely are anaplastic features of malignancy present.
This study sought to determine if chromosomal aberrations correlate with
increased risk of tumor recurrence. Observation shows that while the majority of
PA have a normal karyotype, a portion have highly abnormal karyotypes; the
clinical significance of which is unclear.
Methods: Pathology archives were queried for PA between mid-2008 and mid2017. Review included chromosome, FISH, microarray, molecular results,
cytogenetic methods, histopathology, tumor location, patient age, extent of
surgical resection, chemotherapy, radiotherapy, and outcome. Karyotypes were
defined as “aberrant” if there were multiple bizarre chromosome abnormalities,
multiple telomeric association (tas) figures or translocations, or multiple dicentric
chromosomes. Routine cell culture methods were used with mechanical +/enzymatic disaggregation, alpha-MEM medium, and monolayer coverslip
cultures with harvest as soon as feasible to capture metaphase cells.
Results: Of 64 cultured PA, 4 failed to grow. Karyotypes were normal (n=32),
simple (n=3), hyperdiploid (n=12), or aberrant (n=13). Four patients had a
second tumor resection; 2 had aberrant and 2 had normal karyotypes on the
initial and repeat studies. Of the 13 patient tumors with aberrant karyotypes, 6
tumors (CMH cases 1-5) demonstrated tas, dicentrics, subclones, etc., and two
(CMH cases 6, 7) had multiple cells with an excess of aberrant chromosomes.
Four tumors (CMH cases 8-13 – not shown) had a normal karyotype with one or
two highly aberrant cells; of these, one patient with two resections (CMH cases
11 & 12) showed two highly aberrant cells on both the initial and second study.
Discussion: Highly aberrant karyotypes are unexpected in benign tumors. PA,
is a histologically benign tumor with ~95% 10 year overall survival. Repeatedly
finding highly aberrant karyotypes in some of these tumors begs the question of
clinical significance. How should these karyotypes be interpreted? Finding the
abnormalities in tumors resected twice suggests an ongoing cellular/biologic
process specific to that tumor tissue. The repeat finding of tas and dicentrics
suggests a role for telomere dysfunction in these tumors. This is consistent with
up-regulation of TRF1 and TRF2 (TTAGGG repeat-binding factors) occurring in
the early stages of LGG carcinogenesis, which is characterized by short
telomeres, genomic instability, low proliferative rate and prolonged life span (1).
Limitations of the study: Data are limited – few patients, inconsistent FISH,
microarray and molecular studies were done; no sequence analysis. Multiple
factors play a role in patient outcome including tumor location and resectability.
Conclusions: Additional cases, additional follow-up, additional genomic
analyses are needed. Next step: WES of rearranged cases is planned.
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45,X,tas(Y;16)(q12;q24)[1]
91,slx2[3]
45,sl,der(21)t(12;21)(q13;q22)[1]
46,XY,der(21)t(12;21)(q13;q22)[1]
Subtotal;
Residual tumor; 45,XY,tas(15;21)(q26;q22)[1]
Microarray - normal
CMH 1 8.5y M Suprasellar, 3rd
History of ADHD 92,XXYY,tas(16;21)(q24;q22),+add(21)(q22)[1]
FISH - +7
ventricle; midline
91,XXY,tas(Y;21)(q12;q22)[2]
92,XXYY,tas(16;18)(q24;q23)x2[1]
46,XY[7]
92,XXYY[2]
91<4n>,XXXX,der(5)t(5;9)(p14;q13),+7,+7,4,dic(9;16)(p10;q24)[1]
89<4n>,XXX,-X,der(5)t(5;9)(p14;q13),dic(5;9)(p14;p10),+7,+7,14,-15,-16[1]
88,<4n>XX,-X,-X,No residual
,der(5)t(5;9)(p14;q13),+7,+7,der(9;14)(p10;q10),
Microarray - +7, 7q34 dup
GTR;
tumor at 6 mo
dic(14;16)(q10;q24)[1]
FISH - +7,+7 with 7q34
CMH 2 10y F
Basal ganglia, post surgery;
89,<4n>XXX,-X,dic(1;17)(p36.3;q10),add(4)(p16),der(5)t(5;9)
dupx2
Right, parietal lobe Homonymous
(p14;q13),dic(5;?)(p11.2;?),+7,+7,der(9;14)(p10;q10),
hemianopsia
dic(14;16)(q10;q13)[1]
91<4n>,XXXX,der(5;14)(q10;q10),dic(5)t(5;?;14)(p15;?;q10),
+7,+7,-16[1]
90,<4n>XXXX,trc(3;5;17)(p13;q10q22;q10)x2,dic(5;12)(q31;q24
.1)x2,+5,+5,der(12)t(3;12)(p21;p13)x2,add(22)(q12)x2,+2mar[1]
46,XX[14]
46-48,XY,+5,+6,+11,dic(14;22)(p13;p13)[cp4]/465y post surgery 47,XY,+5,+6,+11,dic(14;22)(p13;p13),dic(17;?;20)(q25;?;q13.3)[
cp2]/
doing well
History of autism, 47-48,XY,+5,+6,+11,dic(14;20)(p13;q13.3)[cp4]/
ADHD
44-48,XY,+5,+6,+11,dic(20;22)(q13.3;p13)[cp5]/
48,XY,+4,+5,+6,+7,-14,dic(19;22)(p13.3;p13)[1]/46,XY[3]

nd

47,XY,+7[10]/
47,sl,add(14)(p11.2)[1]/
47,sdl1,tas(11;16)(qter;qter)[1]/
Tumor regrowth,
46,sdl1,add(2)(p21),-20[1]/
Subtotal ;
chemo -> tumor
87,sdl1x2,tas(7;17)(qter;qter)x2,-16,-16,-19,-19,-21,-21,+mar[1]/
Diencephalon, growth -> XRT;
CMH 4 5.5 y M
47,sl,tas(13;22)(pter;pter),tas(14q;16q),tas(17q;19p)[1]/
suprasellar, optic Neurological
46,sl,dic(9;14)(q12;p13),der(17)t(9;17)(q12;q25)[1]/
system, midline sequela; alive,
47,sl,del(11)(q11),add(17)(q25)[1]/
stable
46,XY,tas(6;13)(qter;qter)[1]
46,XY,tas(3;9)(qter;qter),tas(12;17)(pter;qter)[1]/
46,XY[1]

nd

CMH 3

9y M

GTR;
Cerebellum,
midline

45,XY,dic(5;18)(p15.3;p11.3),inc[4]
45,XY,dic(5;12)(p15.3;p13),inc[3]
45,XY,dic(5;8),inc[2]
38-52 chromosomes with random abnormalities[11]
46,XY[14]

CMH
10.5y M
5a

GTR;
Cerebellum,
midline

Residual tumor

CMH
13.6y M
5b

GTR
re-resection;
Cerebellum,
midline

55,XY,+X,+5,+7,+9,+10,+11,+13,+16,+20[11]
Residual tumor; 55,sl,tas(5;16)(p15.3;q24),tas(12;17)(p13.3;q25)[1]
4th ventricle
55,sl,tas(5;?;12)(p15.3;?;p13.3)[1]
outlet obstruction 54,sl,-Y,tas(5;8)(p15.3;p23)[1]
46,XY[6]

FISH - BRAF no dup

nd

Partial resection;
Residual tumor; 46,XY[14]
CMH 6 16.5y M
Cerebellum,
Prolonged rehab 43-49 chromosomes with excessive rearrangements[cp6]
midline

CMH 7 15y F

GTR;
No residual 47,XX,+7[12]
Hypothalamus, tumor at 1yr post 40-49 chromosomes with excessive aberrations[cp7]
surg
46,XX[1]
midline

Microarray - normal

Microarray - +7, 7q34 dup
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